This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Finasteride

Read time: 1 mins
Marketing start date: 23 Nov 2024
...
 

Summary of product characteristics


Effective Time

20221013

Version

4

Spl Product Data Elements

Finasteride Finasteride FINASTERIDE FINASTERIDE DOCUSATE SODIUM FD&C BLUE NO. 2 HYDROXYPROPYL CELLULOSE (1600000 WAMW) FERRIC OXIDE YELLOW LACTOSE MONOHYDRATE MAGNESIUM STEARATE CELLULOSE, MICROCRYSTALLINE STARCH, CORN SODIUM STARCH GLYCOLATE TYPE A POTATO TALC TITANIUM DIOXIDE SHELLAC FERROSOFERRIC OXIDE HYPROMELLOSES blue ROUND ZE;56

Application Number

ANDA078900

Brand Name

Finasteride

Generic Name

Finasteride

Product Ndc

70771-1152

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1152-0 in bottle of 1000 tablets Finasteride Tablets USP, 5 mg R x only 1000 tablets Finasteride Tablets, 5 mg

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.